In conclusion, our research provides compelling evidence supporting the efficacy of the anti-CD47 antibody and anti-CTLA4 antibody combination in treating NSCLC, thereby proposing meaningful avenues for future clinical trials addressing NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.